All In Biotech

Drug Trial Radar · NCT07681596

A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma

A Modular, Phase I/II, Open-label, Multicentre Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Efficacy of AZD4045, an Allogeneic Chimeric Antigen Receptor-T Cell (CAR-T) Therapy Targeting B Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

101

Planned (sponsor's estimate)

Start

Jul 27, 2026

Primary completion

Mar 6, 2031

Study completion Mar 6, 2031

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jul 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety, tolerability, preliminary efficacy, cellular kinetics, and other exploratory endpoints of AZD4045 as a monotherapy and in association with daratumumab and aldesleukin for the treatment of adult participants with RRMM.

Conditions

  • Relapsed or Refractory Multiple Myeloma

Interventions

  • AZD4045Biological

    Allogeneic Chimeric Antigen Receptor T cell (CAR-T) Therapy Targeting B Cell Maturation Antigen (BCMA)

  • DaratumumabDrug

    Anti-CD38 monoclonal antibody

  • AldesleukinDrug

    Recombinant human IL-2

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse events (AEs) and serious AEs (SAEs)Time frame: Through study completion, an average of 2 years
  2. Dose-limiting toxicities (DLT)Time frame: 28 days

Locations

12 sites in 2 countries. Site status is shown where the registry gives one.

  • Research Site

    Duarte, California · Recruiting

  • Research Site

    Denver, Colorado · Not yet recruiting

  • Research Site

    Tampa, Florida · Not yet recruiting

  • Research Site

    Atlanta, Georgia · Not yet recruiting

  • Research Site

    St Louis, Missouri · Not yet recruiting

  • Research Site

    Hackensack, New Jersey · Not yet recruiting

  • Research Site

    Cleveland, Ohio · Withdrawn

  • Research Site

    Nashville, Tennessee · Not yet recruiting

  • Research Site

    Houston, Texas · Recruiting

  • Research Site

    Milwaukee, Wisconsin · Withdrawn

  • Research Site

    Camperdown, Australia · Not yet recruiting

  • Research Site

    East Melbourne, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.